Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma

Leukemia

Volumn 27, Issue 5, 2013, Pages 1165-1171

  Huo, J ^a   Xu, S ^a,b   Lin, B ^c   Chng, W J ^c,d,e   Lam, K P ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Akt; FAIM; IGF 1; IRF4; multiple myeloma

Indexed keywords

BORTEZOMIB; FAS APOPTOSIS INHIBITORY MOLECULE; INTERFERON REGULATORY FACTOR 4; PROTEIN INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERFERON REGULATORY FACTORS; MULTIPLE MYELOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84877603442     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.326     Document Type: Article

References (42)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
3. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
4. Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011; 62: 249-264.
5. Thomas ED, Lochte Jr HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-496.
6. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol 1982; 68: 215-223.
7. Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J. Natl. Cancer Inst. 1986; 76: 1269-1273.
8. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
9. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
10. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
11. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
12. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
13. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
14. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
15. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
16. Uranishi M, Iida S, Sanda T, Ishida T, Tajima E, Ito M et al. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. Leukemia 2005; 19: 1471-1478.
17. Schneider TJ, Fischer GM, Donohoe TJ, Colarusso TP, Rothstein TL. A novel gene coding for a Fas apoptosis inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes. J Exp Med 1999; 189: 949-956.
18. Sole C, Dolcet X, Segura MF, Gutierrez H, Diaz-Meco MT, Gozzelino R et al. The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-kapp B signaling. J Cell Biol 2004; 167: 479-492.
19. Huo J, Xu S, Guo K, Zeng Q, Lam KP. Genetic deletion of faim reveals its role in modulating c-FLIP expression during CD95-mediated apoptosis of lymphocytes and hepatocytes. Cell Death Differ 2009; 16: 1062-1070.
20. Huo J, Xu S, Lam KP. Fas apoptosis inhibitory molecule regulates T cell receptormediated apoptosis of thymocytes by modulating Akt activation and Nur77 expression. J Biol Chem 2010; 285: 11827-11835.
21. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004; 1693: 167-176.
22. Kaku H, Rothstein TL. Fas apoptosis inhibitory molecule enhances CD40 signaling in B cells and augments the plasma cell compartment. J Immunol 2009; 183: 1667-1674.
23. Kaku H, Rothstein TL. Fas apoptosis inhibitory molecule expression in B cells is regulated through IRF4 in a feed-forward mechanism. J Immunol 2009; 183: 5575-5581.
24. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17: 226-230.
25. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85: 1903-1912.
26. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994; 152: 117-128.
27. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112.
28. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-2989.
29. Turner Jr. CA, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994; 77: 297-306.
30. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893.
31. Freund GG, Kulas DT, Mooney RA. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 1993; 151: 1811-1820.
32. Menu E, van Valckenborgh E, Van Camp B, Vanderkerken K. The role of the insulinlike growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115: 49-57.
33. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
34. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-2861.
35. Vanderkerken K, Asosingh K, Braet F, Van RI, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999; 93: 235-241.
36. Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 2006; 20: 174-176.
37. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
38. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
39. Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
40. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991-6000.
41. Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K et al. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 2009; 114: 3890-3898.
42. Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara RC et al. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol 2011; 64: 75-82.